1. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP).;Tomczyk;MMWR Morb Mortal Wkly Rep,2014
2. Recommendations from the National Vaccine Advisory committee: standards for adult immunization practice.;Orenstein;Public Health Rep,2014
3. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).;CDC;MMWR Morb Mortal Wkly Rep,2012
4. Incremental cost-effectiveness of 13-valent pneumococcal conjugate vaccine for adults age 50 years and older in the United States.;Stoecker;J Gen Intern Med,2016
5. Update: pneumococcal polysaccharide vaccine usage—United States.;CDC;MMWR Morb Mortal Wkly Rep,1984